WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 30.92
-0.16 (-0.51%)
Jun 15, 2026, 4:09 PM HKT
WuXi Biologics Stock Forecast
Stock Price Forecast
According to 25 analysts polled by S&P Global, WuXi Biologics stock has a consensus rating of "Strong Buy" and an average price target of $46.88. The average 1-year stock price forecast is 51.62% higher than the current stock price, while the lowest is $30.60 (-1.03%) and the highest is $78.48 (+153.82%).
Price Target: $46.88 (+51.62%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for WuXi Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 17 | 17 | 16 | 17 | 17 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 4 | 4 | 5 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 26 | 27 | 25 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $54.49 | Buy | Maintains | $54.49 | +76.23% | Jun 9, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $48.00 | Buy | Maintains | $48.00 | +55.24% | Jun 2, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $50.00 | Buy | Maintains | $50.00 | +61.71% | Jun 1, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $49.30 | Buy | Maintains | $49.30 | +59.44% | May 26, 2026 |
Unknown Analyst Citi No rating | Citi | Buy Maintains $42.00 | Buy | Maintains | $42.00 | +35.83% | Apr 13, 2026 |
Financial Forecast
Revenue This Year
25.22B
from 21.79B
Increased by 15.75%
Revenue Next Year
29.59B
from 25.22B
Increased by 17.33%
EPS This Year
1.43
from 1.33
Increased by 7.87%
EPS Next Year
1.72
from 1.43
Increased by 20.07%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 25.9B | ||
| Avg | 25.2B | ||
| Low | 25.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 18.9% | ||
| Avg | 15.7% | ||
| Low | 14.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 1.43 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 7.9% | ||
| Low | - |